Roche v. Cipla: The ‘Mint’ interviews Roche India’s MD on the recently concluded Tarceva litigation


The Mint recently carried an interview of Mr. Girish Telang, managing director of Roche Scientific India Pvt Ltd, the Indian unit of Switzerland-based F Hoffmann-La Roche Ltd. Incidentally this interview seems to be one of the few public statements by Roche, in regards, its high profile litigation against Cipla over Tarceva. (We’ve blogged about the Roche v. Cipla litigation here.) SpicyIP however was rather surprised by the re-statement of some facts by Mr. Telang, since all these facts were very…


Read More »

India-USPTO conference on TK & patenting kicks off in New Delhi


The Financial Express reports that India, the United States Patents & Trademark Office (USPTO) along with representatives of Saarc countries and WIPO are having a three day conference in New Delhi to deal with developing countries concerns in regards the protection of traditional knowledge (TK), genetic resources & folklore – all of them being subjects not adequately covered by TRIPS. Readers may remember that Sumati had, way back in Novemebr 2007, pointed out to an ET article on the efforts…


Read More »
Drug Regulation

Pointing Fingers: Accusations fly as Roche-Cipla continue to lockhorns.


The latest in the Roche- Cipla patent war are allegations of wrongful promotion of Erlocip. This is the same drug that Roche held a patent for, but Cipla continued to manufacture in India. Readers will remember Shamnad’s extensive post on the Roche-Cipla judgment that revolved around this very drug. As per the letter dated 27 March, 2008, Cipla allegedly distributed promotional literature on Erlocip for the treatment of four kinds of cancer (non-small lung cell, pancreatic, neck & head cancer…


Read More »

Gauri Kamath’s Coverage of the Proposed Bayh Dole Bill


In an exceptionally well written and researched piece on the proposed Bayh Dole style bill in India, Gauri Kamath of Businessworld asks: “Is Greater Patenting of Research Funded by Taxpayers Beneficial?�”As readers may be aware, SpicyIP has been pushing for more transparency around this bill. We are extremely happy to note that journalists such as Gauri are making an effort to understand the various nuances and complex issues around this proposed bill. And their incisive analysis and coverage will go…


Read More »
Copyright

Moser Baer in Tamil film titles tussle


So we’re back to a pet SpicyIP subject (beyond the pharma buzz): home entertainment and the Moser Baer (MB) phenomenon. This time around, the optical disc manufacturer-turned-home video giant is in a tussle over alleged copyright infringement of its newly-expanded Tamil film titles’ list. Although the question right now is preliminary and primarily jurisdictional, it will be interesting to see whether similar issues get raised by rights-claimants in other non-Mumbai film industries. What I gather from the latest HT report…


Read More »

Parallel Imports: Bangladesh as a New Business Opportunity for Indian Generics?


In a very incisive post, Mrinalini spoke about the scope of Section 107A of the Indian Patents Act, a provision dealing with the tricky issue of “parallel imports”. Does this provision present yet another business opportunity for our home grown generic companies? How does this implicate the mandate to grant the patentee an “exclusive right to import” under TRIPS? I had discussed some of these issues with Joe C Mathew of the Business Standard some weeks back. Owing to a…


Read More »

Roche vs CIPLA: The Rhetoric of Patent Busting


The Indian Express carried a short note of mine on the Roche vs CIPLA decision by Justice Ravinder S Bhat. I’ve reproduced the text below. For our previous posts on this issue, see here.Unless Roche is able to demonstrate empirically that CIPLA’s lower prices for Erlotinib (the lung cancer drug in issue) does not really translate to increased access to poor patients, it is difficult to see how Justice Bhat’s order will be overturned in appeal. “The rhetoric of ‘patent…


Read More »
Copyright

SpicyIP Tidbit: Aamir Khan’s copyright saga


Recently, SpicyIP reported on how Aamir Khan had strong views about the protection of copyright and was completely anti-piracy. Strong views. Perhaps, we know why. As per reports, the Metropolitan Court (pursuant to summons on February 10, 2008) on Tuesday summoned Bollywood actor and producer Aamir Khan to depose as witness in an old case of copyright violation of his acclaimed movie Lagaan in Mumbai. The case pertains to the seizure of seven VCDs of the 2001 release Lagaan and…


Read More »
Patent

Spicy IP:Stem cell Patents.


Patent issues in the life sciences domain continue to generate much contentious debate especially so in sensitive niche areas such as stem cell research and therapy.With law and regulation struggling to keep pace with scientific and medical advance, the divide between the opponents and proponents widens. Stem Cell Patents continue to occupy the incandescent zone and evolving jurisprudence in the west we hope will lend us some further light and insight ICMR in India has been active in setting the…


Read More »

SpicyIP Tidbit: AstraZeneca Cuts a Deal with Ranbaxy


The cat is finally out of the bag. After ostensibly denying reports of any kind of settlement with Ranbaxy, AstraZeneca has concluded an agreement with Ranbaxy Pharmaceuticals Inc, a wholly-owned subsidiary of Ranbaxy Laboratories Ltd, which would allow Ranbaxy to start exclusive sales of a generic version of ulcer drug Nexium from May 27, 2014 in the US. This is in addition to the 180-day period following that date during which time Ranbaxy shall have the exclusive marketing rights to…


Read More »